Echocardiographic evaluation of the early cardiotoxic effect of hematopoietic stem cell transplantation in patients with hematologic malignancies

References

• Gratwohl A, Baldomero H, Passweg J, et al. Accreditation Committee of the European Group for Blood and Marrow Transplantation (EBMT) in cooperation with the Working Parties Acute (ALWP) and Chronic Leukemias (CLWP) and the Lymphoma Working Party. Hematopoietic stem cell transplantation for hematological malignancies in Europe. Leukemia. 2003;17:941–959.
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Baldomero H, Horisberger B, Schmid C. Current trends in hematopoietic stem cell transplantation in Europe. Blood. 2002;100:2374–2386.
   PubMed Web of Science ®Google Scholar
• Poręba M, Poręba R, Gać P, et al. Heart rate variability and heart rate turbulence in patients with hematologic malignancies subjected to high-dose chemotherapy in the course of hematopoietic stem cell transplantation. Ann Noninvasive Electrocardiol. 2014;19:157–165.
   PubMed Web of Science ®Google Scholar
• Poręba M, Gać P, Usnarska-Zubkiewicz L, et al. Endothelial function in patients with hematologic malignancies undergoing high-dose chemotherapy followed by hematopoietic stem cell transplantation. Cardiovasc Toxicol. 2015 Apr 9; [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Armenian S, Sun C, Shannon T, et al. Incidence and predictors of congestive heart failure after autologous hematopoietic cell transplantation. Blood. 2011;118: 6023–6029.
   PubMed Web of Science ®Google Scholar
• Paulus W, Tschöpe C, Sanderson J, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28:2539–2550.
   PubMed Web of Science ®Google Scholar
• Khouri S, Maly G, Suh D, Walsh T. A practical approach to the echocardiographic evaluation of diastolic function. J Am Soc Echocardiogr. 2004;17:290–297.
   PubMed Web of Science ®Google Scholar
• Bess RL, Khan S, Rosman HS, et al. Technical aspects of diastology: why mitral inflow and tissue Doppler imaging are the preferred parameters? Echocardiography. 2006;23:332–339.
   PubMed Web of Science ®Google Scholar
• Sahin T, Celikyurt U, Kilic T, et al. Respiratory changes in the E/A wave pattern can be an early sign of diastolic dysfunction: an echocardiographic long-term follow-up study. Med Sci Monit. 2012;18:79–84.
   Google Scholar
• Jensen BC, McLeod HL. Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity. Pharmacogenomics. 2013;14:205–213.
   PubMed Web of Science ®Google Scholar
• Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56:185–229.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710–717.
   PubMed Web of Science ®Google Scholar
• Lipshultz S, Lipsitz S, Sallan S, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23:2629–2636.
   PubMed Web of Science ®Google Scholar
• Tichelli A, Bhatia S, Socié G. Cardiac and cardiovascular consequences after haematopoietic stem cell transplantation. Br J Haematol. 2008;142:11–26.
   PubMed Web of Science ®Google Scholar
• Tichelli A, Passweg J, Wójcik D, et al. EBMT Late Effects Working Party. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2008;93:1203–1210.
   PubMed Web of Science ®Google Scholar
• Cardinale D, Sandri M, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109:2749–2754.
   PubMed Web of Science ®Google Scholar
• Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28:3910–3916.
   PubMed Web of Science ®Google Scholar
• Snowden JA, Hill GR, Hunt P, et al. Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplant. 2000;26:309–313.
   PubMed Web of Science ®Google Scholar
• Roziakova L, Mistrik M, Batorova A, et al. Can we predict clinical cardiotoxicity with cardiac biomarkers in patients after haematopoietic stem cell transplantation? Cardiovasc Toxicol. 2015;15:210–216.
   PubMed Web of Science ®Google Scholar
• Sawaya H, Sebag I, Plana J, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5:596–603.
   PubMed Web of Science ®Google Scholar
• Roodpeyma S, Moussavi F, Kamali Z. Late cardiotoxic effects of anthracycline chemotherapy in childhood malignancies. J Pak Med Assoc. 2008;58:683–687.
   PubMedGoogle Scholar
• Velensek V, Mazic U, Krzisnik C, et al. Cardiac damage after treatment of childhood cancer: a long-term follow-up. BMC Cancer. 2008;8:141
   PubMed Web of Science ®Google Scholar
• Bulock Bu’Lock F, Mott MG, Oakhill A, Martin RP. Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and pathophysiology. Br Heart J. 1995;73:340–350.
   PubMedGoogle Scholar
• Simůnek T, Stérba M, Popelová O, et al. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep. 2009;61:154–171.
   PubMed Web of Science ®Google Scholar
• Dessì M, Piras A, Madeddu C, et al. Long-term protective effects of the angiotensin receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress and myocardial dysfunction. Exp Ther Med. 2011;5:1003–1009.
   Google Scholar
• Brunello A, Kapoor R, Extermann M. Hyperglycemia during chemotherapy for hematologic and solid tumors is correlated with increased toxicity. Am J Clin Oncol. 2011;34:292–296.
   PubMed Web of Science ®Google Scholar
• Duan W, Shen X, Lei J, et al. Hyperglycemia, a neglected factor during cancer progression. Biomed Res Int. 2014;4:461917
   Google Scholar
• Zeng L, Biernacka KM, Holly JM, et al. Hyperglycaemia confers resistance to chemotherapy on breast cancer cells: the role of fatty acid synthase. Endocr Relat Cancer. 2010;17:539–551.
   PubMed Web of Science ®Google Scholar
• Sciacca L, Vigneri R, Tumminia A, et al. Clinical and molecular mechanisms favoring cancer initiation and progression in diabetic patients. Nutr Metab Cardiovasc Dis. 2013;23:808–815.
   PubMed Web of Science ®Google Scholar
• Asensio-López MC, Lax A, Pascual-Figal DA, et al. Metformin protects against doxorubicin-induced cardiotoxicity: involvement of the adiponectin cardiac system. Free Radic Biol Med. 2011;51:1861–1871.
   PubMed Web of Science ®Google Scholar
• Jalving M, Gietema JA, Lefrandt JD, et al. Metformin: taking away the candy for cancer? Eur J Cancer. 2010;46:2369–2380.
   PubMed Web of Science ®Google Scholar